FLT3 and acute myeloid leukemia: However, being relatively non-specific, sorafenib was poorly tolerated, and only 25% of children with FLT3-ITD AML received maintenance sorafenib according to the study protocol; frequent dose modifications, dose holds, and drug discontinuation occurred [130,131].